June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Baseline characteristics and response to intravitreal ranibizumab therapy for age-related macular degeneration
Author Affiliations & Notes
  • Misa Suzuki
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Norihiro Nagai
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Kanako Izumi-Nagai
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Hajime Shinoda
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Takashi Koto
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Atsuro Uchida
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • HIroshi Mochimaru
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Kenya Yuki
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Kazuo Tsubota
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Yoko Ozawa
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Footnotes
    Commercial Relationships Misa Suzuki, None; Norihiro Nagai, None; Kanako Izumi-Nagai, None; Hajime Shinoda, None; Takashi Koto, None; Atsuro Uchida, None; HIroshi Mochimaru, None; Kenya Yuki, None; Kazuo Tsubota, AcuFocus, Inc (C), Allergan (F), Bausch Lomb Surgical (C), Functional visual acuity meter (P), JiNS (P), Kissei (F), Kowa (F), Santen, Inc. (F), Otsuka (F), Pfizer (C), Thea (C), Echo Denki (P), Nidek (F), Ophtecs (F), Wakasa Seikatsu (F), CEPT Company (P); Yoko Ozawa, Wakasa Seikatsu.Co.,Ltd. (F), NOVARTIS Pharmacetutical Co., Ltd (F), Senju Pharmaceutical Co., Ltd. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4093. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Misa Suzuki, Norihiro Nagai, Kanako Izumi-Nagai, Hajime Shinoda, Takashi Koto, Atsuro Uchida, HIroshi Mochimaru, Kenya Yuki, Kazuo Tsubota, Yoko Ozawa, Laboratory of Retinal Cell Biology,Keio University Center for Integrated Medical Research; Baseline characteristics and response to intravitreal ranibizumab therapy for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4093.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To study the baseline characteristics and response to intravitreal ranibizumab (IVR) therapy for age-related macular degeneration (AMD).

Methods: We reviewed clinical records of 119 eyes in 118 AMD patients who underwent IVR 3 times for induction therapy, and additionally when fluid or visual loss was observed during a 12-month follow-up. Baseline characteristics were analyzed, and responders and non-responders were identified at month 12. Patients whose best corrected visual acuity (BCVA) worsened more than 0.2 in logMAR score were, and those with increased or new exudative fundus findings or an increased central retinal thickness more than 100 micrometers were, considered to be non-responders as judged by BCVA, and by fundus findings, respectively. Adjusted odds ratios (ORs) for responders and non-responders, and 95% confidence intervals (CIs) were estimated with logistic regression models.

Results: Non-responders represented 16.8% of the AMD patients, as judged by BCVA, and 21.0%, as judged by fundus findings. The average age of non-responders by BCVA was higher than responders. Fibrovascular pigment epithelial detachment (PED) (odds ratio 3.77, 95% CI 1.03- 13.83) and serous PED (odds ratio 4.86, 95% CI 1.17-20.11) at baseline were associated with non-response as judged by BCVA . Fibrovascular PED (OR 7.07, 95% CI 2.30-21.72), and type 1 choroidal neovascularization (OR 4.06, 95% CI 1.13-14.65) at baseline were associated with non-response, as judged by fundus findings.

Conclusions: Although most AMD patients responded to IVR therapy, non-responders had clinical characteristics at baseline that might be informative for managing their treatment.

Keywords: 412 age-related macular degeneration • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×